Hancock Whitney’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.9M | Sell |
233,542
-8,923
| -4% | -$629K | 0.26% | 100 |
|
|
2025
Q4 | $16.3M | Sell |
242,465
-3,756
| -2% | -$253K | 0.29% | 95 |
|
|
2025
Q3 | $18.1M | Buy |
246,221
+10,326
| +4% | +$686K | 0.33% | 88 |
|
|
2025
Q2 | $12.3M | Buy |
235,895
+32,077
| +16% | +$1.83M | 0.23% | 102 |
|
|
2025
Q1 | $13M | Buy |
203,818
+83,007
| +69% | +$4.82M | 0.42% | 54 |
|
|
2024
Q4 | $5.78M | Buy |
120,811
+104,015
| +619% | +$5.33M | 0.18% | 91 |
|
|
2024
Q3 | $961K | Buy |
16,796
+80
| +0.5% | +$4.59K | 0.03% | 321 |
|
|
2024
Q2 | $875K | Buy |
16,716
+11,286
| +208% | +$495K | 0.03% | 328 |
|
|
2024
Q1 | $221K | Sell |
5,430
-439
| -7% | -$16.5K | 0.01% | 606 |
|
|
2023
Q4 | $217K | Sell |
5,869
-8
| -0.1% | -$301 | 0.01% | 610 |
|
|
2023
Q3 | $225K | Sell |
5,877
-207
| -3% | -$8.48K | 0.01% | 577 |
|
|
2023
Q2 | $219K | Sell |
6,084
-2,345
| -28% | -$80K | 0.01% | 588 |
|
|
2023
Q1 | $322K | Sell |
8,429
-1,148
| -12% | -$53.8K | 0.01% | 525 |
|
|
2022
Q4 | $545K | Sell |
9,577
-20
| -0.2% | -$1.02K | 0.02% | 415 |
|
|
2022
Q3 | $379K | Buy |
9,597
+386
| +4% | +$17.1K | 0.02% | 470 |
|
|
2022
Q2 | $405K | Sell |
9,211
-670
| -7% | -$29K | 0.02% | 468 |
|
|
2022
Q1 | $394K | Buy |
9,881
+128
| +1% | +$4.56K | 0.01% | 516 |
|
|
2021
Q4 | $392K | Sell |
9,753
-67
| -0.7% | -$2.5K | 0.01% | 528 |
|
|
2021
Q3 | $399K | Sell |
9,820
-300
| -3% | -$12.5K | 0.01% | 521 |
|
|
2021
Q2 | $460K | Sell |
10,120
-14,578
| -59% | -$645K | 0.01% | 575 |
|
|
2021
Q1 | $1.03M | Sell |
24,698
-394
| -2% | -$18K | 0.04% | 399 |
|
|
2020
Q4 | $1.07M | Buy |
25,092
+32
| +0.1% | +$1.15K | 0.04% | 376 |
|
|
2020
Q3 | $659K | Sell |
25,060
-38
| -0.2% | -$1.06K | 0.02% | 454 |
|
|
2020
Q2 | $673K | Sell |
25,098
-9,176
| -27% | -$207K | 0.03% | 449 |
|
|
2020
Q1 | $617K | Buy |
34,274
+9,647
| +39% | +$183K | 0.02% | 473 |
|
|
2019
Q4 | $437K | Sell |
24,627
-11,091
| -31% | -$192K | 0.01% | 593 |
|
|
2019
Q3 | $554K | Sell |
35,718
-9,721
| -21% | -$160K | 0.02% | 564 |
|
|
2019
Q2 | $781K | Buy |
45,439
+5,179
| +13% | +$83.6K | 0.03% | 508 |
|
|
2019
Q1 | $648K | Buy |
40,260
+8,630
| +27% | +$140K | 0.02% | 557 |
|
|
2018
Q4 | $463K | Sell |
31,630
-14,485
| -31% | -$231K | 0.02% | 611 |
|
|
2018
Q3 | $838K | Buy |
46,115
+4,052
| +10% | +$71K | 0.02% | 512 |
|
|
2018
Q2 | $710K | Buy |
+42,063
| New | +$795K | 0.03% | 395 |
|
Other funds holding HALO
VCM
VPM
Hancock Whitney's HALO Position: Q1 2026 in Review
Hancock Whitney reduced its Halozyme (HALO) stake by 3.7% in Q1 2026, selling an estimated $629K and leaving 233,542 shares worth $14.9M. The position accounts for 0.26% of the portfolio, ranked #100.
Hancock Whitney first reported a position in HALO in Q2 2018 and has held it in 32 quarters since. The position peaked at $18.1M in Q3 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.
- Hancock Whitney held 233,542 shares of Halozyme worth $14.9M as of Q1 2026.
- Hancock Whitney sold 8,923 Halozyme shares in Q1 2026, an estimated $629K.
- Halozyme made up 0.26% of Hancock Whitney's portfolio in Q1 2026, its #100 holding.
- Hancock Whitney first reported a position in Halozyme in Q2 2018 and has held it in 32 quarters since.
- Hancock Whitney's Halozyme position peaked at $18.1M in Q3 2025.
- 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.
Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.